Skip to content

HPV Vaccination in Women With Cystic Fibrosis

HPV (Papilloma Human Virus) Vaccination in Young Women With Cystic Fibrosis and Followed in the Auvergne Rhône-Alpes Region

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03265743
Acronym
VACCIN-HPV-MUC
Enrollment
74
Registered
2017-08-29
Start date
2017-09-25
Completion date
2017-12-15
Last updated
2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Papillomavirus Infection

Brief summary

The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19, is an effective method of preventing cervical pathology. Despite this, human papillomavirus vaccination coverage remains low in France. Some women with cystic fibrosis might need a transplantation, which is a factor associated with increased risk of human papillomavirus carriage and cervical pathology. An over-risk of cervical pathology would also be present in non-transplanted women with cystic fibrosis. Particular attention should therefore be paid to vaccination in this population. The objective is to estimate the frequency of human papillomavirus vaccination in young patients with cystic fibrosis, and to evaluate the reasons for non-vaccination.

Interventions

Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
11 Years to 18 Years

Inclusion criteria

* girls with Cystic Fibrosis * followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA) * aged 11 years or older

Exclusion criteria

\- Refusal to respond to the questionnaire

Design outcomes

Primary

MeasureTime frameDescription
Realization of human papillomavirus vaccination15 minutesThe main outcome is the prevalence of human papillomavirus vaccination in young women with Cystic fibrosis. This data is collected using a questionnaire : HPV vaccination performed : yes/no

Secondary

MeasureTime frameDescription
Type of vaccine used15 minutesThis data is collected using a questionnaire : bivalent (Cervarix®) or quadrivalent (Gardasil®)
Respect for the vaccinal plan15 minutesThis data is collected using a questionnaire : number and dates of injections
Reasons for non-vaccination15 minutesIn case of non-vaccination reasons are collected using a multiple choices questionnaire

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026